ZYLOXTB Shares Surge Over 6% After Strong Annual Profit Growth and German Acquisition

Stock News03-18

ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual results, with full-year revenue reaching RMB1.06 billion, a 35.1% year-on-year increase. Net profit surged 143.7% to RMB244 million. The strong performance was attributed to higher sales of core products, accelerated expansion of international operations, and improved operational efficiency. Additionally, ZYLOXTB announced it exercised an option to acquire 11% of Optimed Holding and plans to acquire the remaining 40% in the first half of 2028, taking full ownership. The total estimated cost is up to €41.17 million (approximately RMB326 million). Optimed is a German medical technology company focused on the research, development, production, and global sales of minimally invasive vascular and urological interventional medical devices.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125902375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125902375","market":"other","top_or_hot":-1,"title":"ZYLOXTB Shares Surge Over 6% After Strong Annual Profit Growth and German Acquisition","media":"Stock News","content":"<p>ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual results, with full-year revenue reaching RMB1.06 billion, a 35.1% year-on-year increase. Net profit surged 143.7% to RMB244 million. The strong performance was attributed to higher sales of core products, accelerated expansion of international operations, and improved operational efficiency. Additionally, ZYLOXTB announced it exercised an option to acquire 11% of Optimed Holding and plans to acquire the remaining 40% in the first half of 2028, taking full ownership. The total estimated cost is up to €41.17 million (approximately RMB326 million). Optimed is a German medical technology company focused on the research, development, production, and global sales of minimally invasive vascular and urological interventional medical devices.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZYLOXTB Shares Surge Over 6% After Strong Annual Profit Growth and German Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZYLOXTB Shares Surge Over 6% After Strong Annual Profit Growth and German Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 15:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual results, with full-year revenue reaching RMB1.06 billion, a 35.1% year-on-year increase. Net profit surged 143.7% to RMB244 million. The strong performance was attributed to higher sales of core products, accelerated expansion of international operations, and improved operational efficiency. Additionally, ZYLOXTB announced it exercised an option to acquire 11% of Optimed Holding and plans to acquire the remaining 40% in the first half of 2028, taking full ownership. The total estimated cost is up to €41.17 million (approximately RMB326 million). Optimed is a German medical technology company focused on the research, development, production, and global sales of minimally invasive vascular and urological interventional medical devices.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_FDXS","symbol_name":"微型德国指数","start_time":0,"source_url":"","article_id":"1125902375","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125902375","pubTimestamp":1773818660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1100":"医疗保健设备","BK4588":"碎股","BK1587":"次新股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","02190":"归创通桥","BK1574":"生物医药B类股"},"translate_title":"年度利润强劲增长和德国收购后，ZYLOXTB股价飙升逾6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDXMmain":1,"FDAXmain":1,"FDXSmain":1,"02190":1,"VXUS":1},"content_text":"ZYLOXTB (02190) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 5.17% to HK$21.96, with a turnover of HK$14.90 million. The company reported its annual results, with full-year revenue reaching RMB1.06 billion, a 35.1% year-on-year increase. Net profit surged 143.7% to RMB244 million. The strong performance was attributed to higher sales of core products, accelerated expansion of international operations, and improved operational efficiency. Additionally, ZYLOXTB announced it exercised an option to acquire 11% of Optimed Holding and plans to acquire the remaining 40% in the first half of 2028, taking full ownership. The total estimated cost is up to €41.17 million (approximately RMB326 million). Optimed is a German medical technology company focused on the research, development, production, and global sales of minimally invasive vascular and urological interventional medical devices.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125902375","isCrawlerRequest":true}